Suppr超能文献

氯噻酮和氢氯噻嗪联合阿米洛利多剂量治疗原发性高血压患者的血压疗效:一项析因随机对照试验方案

Efficacy of chlorthalidone and hydrochlorothiazide in combination with amiloride in multiple doses on blood pressure in patients with primary hypertension: a protocol for a factorial randomized controlled trial.

作者信息

Martins Vítor Magnus, Helal Lucas, Ferrari Filipe, Bottino Leonardo Grabinski, Fuchs Sandra Costa, Fuchs Flávio Danni

机构信息

Graduate Program in Cardiology and Cardiovascular Sciences, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

Division of Cardiology, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.

出版信息

Trials. 2019 Dec 16;20(1):736. doi: 10.1186/s13063-019-3909-z.

Abstract

BACKGROUND

Thiazide diuretics have demonstrated favorable blood pressure lowering efficacy, but the equivalent doses of their more common agents, chlorthalidone and hydrochlorothiazide, are still unclear. Further, concerns exist regarding adverse metabolic effects, which may be attenuated with the concomitant administration of a potassium-sparing diuretic, such as amiloride. This trial aims to investigate the efficacy of chlorthalidone and hydrochlorothiazide, in combination with amiloride at different doses, for initial management of patients with primary hypertension.

METHODS/DESIGN: This is a factorial (2 × 2) randomized double-blinded clinical trial comparing the association of a thiazide diuretic (chlorthalidone 25 mg/day or hydrochlorothiazide 50 mg/day) with a potassium-sparing diuretic (amiloride 10 mg/day or amiloride 20 mg/day) in patients with primary hypertension. The primary outcome will be the mean change from baseline in 24-h systolic and diastolic blood pressure measured by ambulatory blood pressure monitoring. The secondary outcomes will be the mean change from baseline in daytime and nighttime systolic and diastolic blood pressure measured by ambulatory blood pressure monitoring, mean change from baseline in systolic and diastolic blood pressure measured by office blood pressure, incidence of adverse events, variation of laboratory parameters, and proportion of patients who achieved blood pressure control. The follow-up will last 12 weeks. For a P alpha of 0.05, power of 80%, standard deviation of 9 mmHg, and absolute difference of 6 mmHg on systolic blood pressure on 24-h ambulatory blood pressure monitoring, it will be necessary to study a total of 76 patients. The sample size will be increased by 10% to compensate for losses, resulting in 84 patients being randomized.

DISCUSSION

Diuretics are pivotal drugs for the treatment of hypertension. Chlorthalidone and hydrochlorothiazide, in combination with amiloride in multiple doses, will be tested in terms of blood pressure lowering efficacy and safety. Since the intensity of blood pressure reduction is the major determinant of reduction in cardiovascular risk in hypertensive patients, this study will help to determine which combination of diuretics represents the most appropriate treatment for this population.

TRIAL REGISTRATION

ClinicalTrials.gov, NCT03928145. Registered on 25 April 2019. Last update on 29 April 2019.

摘要

背景

噻嗪类利尿剂已显示出良好的降压效果,但其更常用的药物氯噻酮和氢氯噻嗪的等效剂量仍不明确。此外,人们对其不良代谢影响存在担忧,而同时服用保钾利尿剂(如阿米洛利)可能会减轻这种影响。本试验旨在研究氯噻酮和氢氯噻嗪联合不同剂量阿米洛利对原发性高血压患者初始治疗的疗效。

方法/设计:这是一项析因(2×2)随机双盲临床试验,比较噻嗪类利尿剂(氯噻酮25毫克/天或氢氯噻嗪50毫克/天)与保钾利尿剂(阿米洛利10毫克/天或阿米洛利20毫克/天)联合应用于原发性高血压患者的情况。主要结局将是通过动态血压监测测得的24小时收缩压和舒张压相对于基线的平均变化。次要结局将是通过动态血压监测测得的白天和夜间收缩压和舒张压相对于基线的平均变化、通过诊室血压测得的收缩压和舒张压相对于基线的平均变化、不良事件发生率、实验室参数变化以及血压控制达标的患者比例。随访将持续12周。对于α为0.05、检验效能为80%、标准差为9毫米汞柱以及24小时动态血压监测的收缩压绝对差值为6毫米汞柱的情况,总共需要研究76名患者。样本量将增加10%以弥补失访,最终84名患者将被随机分组。

讨论

利尿剂是治疗高血压的关键药物。氯噻酮和氢氯噻嗪联合不同剂量的阿米洛利,将在降压疗效和安全性方面进行测试。由于血压降低的强度是高血压患者心血管风险降低的主要决定因素,本研究将有助于确定哪种利尿剂组合是该人群最合适的治疗方法。

试验注册

ClinicalTrials.gov,NCT03928145。于2019年4月25日注册。最后更新于2019年4月29日。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68fa/6916111/dd49e3f74819/13063_2019_3909_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验